/
MRVI
$6.39+$0.17 (+2.73%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$917.5M
148M shares
52-week range
$1.99 – $6.55
96% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.45%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-35.34
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $123.8M | $143.1M | $284.1M | $799.2M | $883.0M | $288.9M | $259.2M | $185.7M |
| Cost of revenue | $60.8M | $66.8M | $79.6M | $140.6M | $169.0M | $148.7M | $150.9M | $152.4M |
| Gross profit | $63.1M | $76.3M | $204.4M | $658.7M | $714.0M | $140.2M | $108.3M | $33.4M |
| Gross margin | 50.9% | 53.3% | 72.0% | 82.4% | 80.9% | 48.5% | 41.8% | 18.0% |
| R&D | $4.5M | $3.6M | $9.3M | $15.2M | $18.4M | $17.3M | $19.2M | $23.3M |
| Operating income | $16.4M | $24.0M | $119.9M | $554.6M | $574.2M | −$31.6M | −$235.6M | −$6.7M |
| EBITDA | $33.2M | $48.2M | $138.3M | $585.8M | $610.0M | $712.4M | −$156.9M | −$147.1M |
| Net income | −$17.7M | −$8.5M | $76.9M | $182.0M | $220.2M | −$119.0M | −$144.8M | −$130.8M |
| Net margin | -14.3% | -5.9% | 27.1% | 22.8% | 24.9% | -41.2% | -55.9% | -70.4% |
| EPS (diluted) | -0.20 | -0.05 | 2.36 | 1.56 | 1.67 | -0.90 | -1.05 | -0.91 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $210M | $-0.11 | $-0.16–$-0.09 | 5 |
| 2027 | $226M | $-0.09 | $-0.19–$-0.04 | 5 |
| 2028 | $243M | $-0.05 | $-0.05–$-0.05 | 1 |
| 2029 | $265M | $-0.14 | $-0.14–$-0.14 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$2.43
Price
$6.39
Implied downside
-62%
Peer comparison
Maravai LifeSciences Holdings, Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.
www.maravai.com- Employees
- 416
- IPO / List date
- Nov 20, 2020
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds MRVI.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 4,264,689 | $12.1M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded MRVI yet.
